![conference banner](/images/conference-banner.jpeg)
Abstract
Background: A series of pyrimidothiadiazinones 5a-n were prepared from aminomethylation of pyrimidinethione 1 with different primary amines and formaldehyde through Mannich reaction. The spectral data of the formed products confirmed the suggested structures.
Method: Most of the newly synthesized compounds were tested for their antimicrobial and anticancer activities. Depending on the obtained results, the newly synthesized compounds possess good to moderate activities. Compound 5e exhibited the highest antibacterial activity measured in 22.1, 18.6, 17.2 and 16.8 mm against Escherichia coli, Staphylococcus aureus, Bacillus subtilis and Pseudomonas aeruginosa, respectively. Compound 5e exhibited highest potency with MIC values of 125, 250, 250, and 500 μg/mL against E. coli, S. aureus, B. subtilis, and P. aureginosa, respectively. Results: Compound 5j exhibited the highest inhibitory effect against breast carcinoma (MCF-7) and hepatocellular carcinoma (HepG2) cell lines. Also, molecular docking against E. Coli Enoyl Reductase; PDB ID (1LXC) and Human Dihydrofolate Reductase; PDB ID (1DLS) revealed high free binding energy and good binding mode. The structure activity relationship (SAR) of tested compounds was also studied.Keywords: Mannich reaction, 1, 3, 5-thiadiazines, molecular docking, antimicrobial and anticancer activities.
Letters in Drug Design & Discovery
Title:Synthesis, Molecular Docking and Pharmacological Study of Pyrimidothiadiazinones and its bis-derivatives
Volume: 14 Issue: 4
Author(s): Sobhi M. Gomha, Ikhlass M. Abbas, Mohamed A. A. Elneairy, Mahmoud M. Elaasser and Bazada K. A. Mabrouk
Affiliation:
Keywords: Mannich reaction, 1, 3, 5-thiadiazines, molecular docking, antimicrobial and anticancer activities.
Abstract: Background: A series of pyrimidothiadiazinones 5a-n were prepared from aminomethylation of pyrimidinethione 1 with different primary amines and formaldehyde through Mannich reaction. The spectral data of the formed products confirmed the suggested structures.
Method: Most of the newly synthesized compounds were tested for their antimicrobial and anticancer activities. Depending on the obtained results, the newly synthesized compounds possess good to moderate activities. Compound 5e exhibited the highest antibacterial activity measured in 22.1, 18.6, 17.2 and 16.8 mm against Escherichia coli, Staphylococcus aureus, Bacillus subtilis and Pseudomonas aeruginosa, respectively. Compound 5e exhibited highest potency with MIC values of 125, 250, 250, and 500 μg/mL against E. coli, S. aureus, B. subtilis, and P. aureginosa, respectively. Results: Compound 5j exhibited the highest inhibitory effect against breast carcinoma (MCF-7) and hepatocellular carcinoma (HepG2) cell lines. Also, molecular docking against E. Coli Enoyl Reductase; PDB ID (1LXC) and Human Dihydrofolate Reductase; PDB ID (1DLS) revealed high free binding energy and good binding mode. The structure activity relationship (SAR) of tested compounds was also studied.Export Options
About this article
Cite this article as:
Gomha M. Sobhi, Abbas M. Ikhlass, Elneairy A. A. Mohamed, Elaasser M. Mahmoud and Mabrouk K. A. Bazada, Synthesis, Molecular Docking and Pharmacological Study of Pyrimidothiadiazinones and its bis-derivatives, Letters in Drug Design & Discovery 2017; 14 (4) . https://dx.doi.org/10.2174/1570180813666160815125409
DOI https://dx.doi.org/10.2174/1570180813666160815125409 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
Call for Papers in Thematic Issues
Navigating the Frontier: Probiotics' Promising Path in Combatting Viral Respiratory Infections, Spotlight on Coronaviridae.
Probiotics, well-known for their role in gut health, show promise in preventing and managing respiratory virus infections, particularly in children and at-risk populations. However, the profound influence of novel pathogenic viral RTIs such as coronaviruses has reshaped perspectives on the potential of probiotics. Despite their potential, significant gaps remain in ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mitochondria as Therapeutic Targets of Estrogen Action in the Central Nervous System
Current Drug Targets - CNS & Neurological Disorders Emerging Strategies and Challenges for Controlled Delivery of Taxanes: A Comprehensive Review
Current Drug Metabolism Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Overview of Current Immunotherapies Targeting Mutated KRAS Cancers
Current Topics in Medicinal Chemistry Tobacco, Inflammation, and Respiratory Tract Cancer
Current Pharmaceutical Design MicroRNAs Involved in Oxidative Stress Processes Regulating Physiological and Pathological Responses
MicroRNA Inhibitors of Chronically Active Ras: Potential for Treatment of Human Malignancies
Recent Patents on Anti-Cancer Drug Discovery Meet the Editorial Board Member
Current Drug Targets Targeting Tyrosine Kinase Receptors in Hepatocellular Carcinoma
Current Cancer Drug Targets Current Status of Novel Pyridine Fused Derivatives as Anticancer Agents: An Insight into Future Perspectives and Structure Activity Relationship (SAR)
Current Topics in Medicinal Chemistry Gadd45 Proteins as Critical Signal Transducers Linking NF-κB to MAPK Cascades
Current Cancer Drug Targets Preparation of Multifunctional Nanoprobes for Tumor-Targeted Fluorescent Imaging and Therapy
Current Drug Targets Extracellular Proteases as Targets for Drug Development
Current Protein & Peptide Science Canonical Matches of Human MicroRNAs with mRNAs: A Broad Matrix of Position and Size
MicroRNA Cisplatin Properties in a Nanobiotechnological Approach to Cancer: A Mini-Review
Current Cancer Drug Targets Anti-Cancer Effects of a New Docosahexaenoic Acid Monoacylglyceride in Lung Adenocarcinoma
Recent Patents on Anti-Cancer Drug Discovery Meet the Editorial Board
Current Cancer Drug Targets Anti-proliferative Properties of miR-20b and miR-363 from the miR-106a-363 Cluster on Human Carcinoma Cells
MicroRNA Anti-Thrombotic Properties of Tomato
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) PET Imaging to Monitor Cancer Therapy
Current Pharmaceutical Biotechnology